Arcturus Therapeutics Holdings Inc. (ARCT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Arcturus Therapeutics Holdings Inc. (ARCT) closed at USD 11.27 on 2026-10-15, a change of +19.4 % over the past year, with a market capitalization of USD 293.89M.

Arcturus Therapeutics Holdings Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Arcturus Therapeutics Holdings Inc. key figures

Previous close

USD 11.27 (2026-10-15)

1-year change

+19.4 %

Market cap

USD 293.89M

Enterprise value

USD 125.34M

P/E ratio (trailing)

-3.11

P/E ratio (forward)

-2.79

EPS (trailing)

-3.33

EPS (forward)

-3.70

PEG ratio

n/a

Price to book

1.71

Revenue growth

-89.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.88

Employees

106

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Arcturus Therapeutics Holdings Inc. and compare it with other stocks.